Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: MINERALOCORTICOID RECEPTOR ANTAGONISTS - THERAPEUTIC USE , . Treffer: 9

2022

Agarwal, R; Anker, SD; Bakris, G; Filippatos, G; Pitt, B; Rossing, P; Ruilope, L; Gebel, M; Kolkhof, P; Nowack, C; Joseph, A, , FIDELIO-DKD, and, FIGARO-DKD, Investigators Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Nephrol Dial Transplant. 2022; 37(6):1014-1023 Doi: 10.1093/ndt/gfaa294 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Ruilope, LM; Agarwal, R; Anker, SD; Bakris, GL; Filippatos, G; Nowack, C; Kolkhof, P; Joseph, A; Mentenich, N; Pitt, B, , FIGARO-DKD study investigators Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Am J Nephrol. 2019; 50(5):345-356 Doi: 10.1159/000503712 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Verheyen, N; Fahrleitner-Pammer, A; Pieske, B; Meinitzer, A; Belyavskiy, E; Wetzel, J; Gaksch, M; Grübler, MR; Catena, C; Sechi, LA; Van, Ballegooijen, AJ; Brandenburg, VM; Scharnagl, H; Perl, S; Brussee, H; März, W; Pilz, S; Tomaschitz, A Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
J Hypertens. 2016; 34(9):1778-86 Doi: 10.1097/HJH.0000000000001004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Senni, M; Paulus, WJ; Gavazzi, A; Fraser, AG; Díez, J; Solomon, SD; Smiseth, OA; Guazzi, M; Lam, CS; Maggioni, AP; Tschöpe, C; Metra, M; Hummel, SL; Edelmann, F; Ambrosio, G; Stewart Coats, AJ; Filippatos, GS; Gheorghiade, M; Anker, SD; Levy, D; Pfeffer, MA; Stough, WG; Pieske, BM New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Eur Heart J. 2014; 35(40):2797-2815 Doi: 10.1093/eurheartj/ehu204 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tomaschitz, A; Ritz, E; Pieske, B; Rus-Machan, J; Kienreich, K; Verheyen, N; Gaksch, M; Grübler, M; Fahrleitner-Pammer, A; Mrak, P; Toplak, H; Kraigher-Krainer, E; März, W; Pilz, S Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Metabolism. 2014; 63(1):20-31 Doi: 10.1016/j.metabol.2013.08.016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Edelmann, F; Wachter, R; Pieske, B; Aldosterone Inhibition in Patients With Heart Failure With Preserved Ejection Fraction Reply.
JAMA. 2013; 310(2):205-207 Doi: 10.1001/jama.2013.7976
Web of Science PubMed FullText FullText_MUG

 

Edelmann, F; Wachter, R; Schmidt, AG; Kraigher-Krainer, E; Colantonio, C; Kamke, W; Duvinage, A; Stahrenberg, R; Durstewitz, K; Loffler, M; Dungen, HD; Tschope, C; Herrmann-Lingen, C; Halle, M; Hasenfuss, G; Gelbrich, G; Pieske, B; Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction The Aldo-DHF Randomized Controlled Trial.
JAMA. 2013; 309(8):781-791 Doi: 10.1001/jama.2013.905 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Maggioni, AP; Anker, SD; Dahlström, U; Filippatos, G; Ponikowski, P; Zannad, F; Amir, O; Chioncel, O; Leiro, MC; Drozdz, J; Erglis, A; Fazlibegovic, E; Fonseca, C; Fruhwald, F; Gatzov, P; Goncalvesova, E; Hassanein, M; Hradec, J; Kavoliuniene, A; Lainscak, M; Logeart, D; Merkely, B; Metra, M; Persson, H; Seferovic, P; Temizhan, A; Tousoulis, D; Tavazzi, L; Heart Failure Association of the ESC Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
Eur J Heart Fail. 2013; 15(10):1173-1184 Doi: 10.1093/eurjhf/hft134 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Edelmann, F; Schmidt, AG; Gelbrich, G; Binder, L; Herrmann-Lingen, C; Halle, M; Hasenfuss, G; Wachter, R; Pieske, B Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
Eur J Heart Fail. 2010; 12(8):874-882 Doi: 10.1093/eurjhf/hfq087 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Med Uni Graz • Impressum